<DOC>
	<DOCNO>NCT01576341</DOCNO>
	<brief_summary>The study assess immunogenicity , safety , efficacy HX575 epoetin alfa administer subcutaneously ( s.c. ) patient suffer anemia due chronic kidney disease ( CKD )</brief_summary>
	<brief_title>HX575 Epoetin Alfa Subcutaneously ( s.c. ) Chronic Kidney Disease ( CKD )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Main Adult male female patient w w/o dialysis treatment Stable i.v . s.c. maintenance therapy EUapproved ESA treatment ESA na√Øve . Adequate iron substitution Main History Pure Red Cell Aplasia ( PRCA ) antierythropoietin ( EPO ) antibodies Contraindications ESA therapy Serum albumin &lt; 3.0 g/dL Immunocompromized patient ( immunosuppressive treatment , chemotherapy ) Hepatitis C infection active treatment hepatitis B human immunodeficiency virus ( HIV ) infection Systemic lupus erythematosus Symptomatic congestive heart failure , Unstable angina pectoris , myocardial infarction within 6 month History malignancy organ system within last 5 year History use nonEU approve ESA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Epoetin alfa , ESA , HX575 , CKD</keyword>
</DOC>